查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1552644

糖尿病非胰岛素疗法市场 - 全球产业分析、规模、份额、成长、趋势和预测，2024-2034 年

Non-insulin Therapies for Diabetes Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
出版日期: | 出版商: Transparency Market Research | 英文 142 Pages | 商品交期: 2-10个工作天内

价格

糖尿病市场的非胰岛素疗法 - 报告范围

TMR 关于全球糖尿病非胰岛素疗法市场的报告研究了过去以及当前的成长趋势和机会，以获得 2024 年至 2034 年预测期内市场指标的宝贵见解。年糖尿病非胰岛素疗法市场，以2024 年为基准年，2034 年为预测年。该报告也提供了2024年至2034年全球糖尿病非胰岛素疗法市场的年复合成长率（CAGR%）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解糖尿病市场的非胰岛素疗法。

市场概况
2023年市场价值 318 亿美元
2034 年市场价值 586 亿美元
复合年增长率 5.8%

该报告深入研究了全球糖尿病非胰岛素疗法市场的竞争格局。全球糖尿病非胰岛素疗法市场的主要参与者已经确定，并且每位参与者都根据各种属性进行了分析。公司概况、财务状况、最新发展和 SWOT 是本报告中介绍的全球糖尿病非胰岛素疗法市场参与者的属性。

目录

第一章：前言

第 2 章：假设与研究方法

第 3 章：执行摘要：市场

第 4 章：市场概览

  • 介绍
  • 概述
  • 市场动态
  • 2020-2034年市场分析与预测

第 5 章：关键见解

  • 管道分析
  • 主要产品/品牌分析
  • 主要併购
  • COVID-19 大流行对该行业的影响

第 6 章：全球市场分析与预测：依药物类别

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依药品类别，2020-2034
    • 双胍类
    • 磺酰脲类
    • 噻唑烷二酮类
    • α-葡萄糖苷酶抑制剂
    • DPP-4 抑制剂
    • GLP-1类似物
    • 钠-葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂
  • 市场吸引力分析：依药品类别

第 7 章：全球市场分析与预测：按管理途径

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依给药途径，2020-2034年
    • 口服
    • 肌肉注射
  • 市场吸引力分析：按给药途径

第 8 章：全球市场分析与预测：按配销通路

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：按配销通路，2020-2034
    • 医院药房
    • 零售药房
    • 网路药房
  • 市场吸引力分析：按配销通路

第 9 章：全球市场分析与预测：按地区

  • 主要发现
  • 市场价值预测：按地区，2020-2034
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力分析：按地区

第 10 章：北美市场分析与预测

第 11 章：欧洲市场分析与预测

第 12 章：亚太市场分析与预测

第 13 章：拉丁美洲市场分析与预测

第 14 章：中东和非洲市场分析与预测

第15章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 市占率分析：依公司分类（2023）
  • 公司简介
    • GSK plc
    • Eli Lilly and Company
    • Sumitomo Pharma
    • Intarcia Therapeutics
    • Servier Laboratories
    • Pfizer Inc.
    • Merck & Co., Inc.
    • Dong-A Pharmaceutical Co., Ltd.
    • Luye Pharma Group
    • Eurofarma Laboratories SA
Product Code: TMRGL86328

Non-insulin Therapies for Diabetes Market - Scope of Report

TMR's report on the global non-insulin therapies for diabetes market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global non-insulin therapies for diabetes market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global non-insulin therapies for diabetes market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the non-insulin therapies for diabetes market.

Market Snapshot
Market Value in 2023US$ 31.8 Bn
Market Value in 2034US$ 58.6 Bn
CAGR5.8%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global non-insulin therapies for diabetes market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global non-insulin therapies for diabetes market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global non-insulin therapies for diabetes market.

The report delves into the competitive landscape of the global non-insulin therapies for diabetes market. Key players operating in the global non-insulin therapies for diabetes market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global non-insulin therapies for diabetes market profiled in this report.

Key Questions Answered in Global non-insulin therapies for diabetes Market Report:

  • What is the sales/revenue generated by non-insulin therapies for diabetes across all regions during the forecast period?
  • What are the opportunities in the global non-insulin therapies for diabetes market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Non-insulin Therapies for Diabetes Market - Research Objectives and Research Approach

The comprehensive report on the global non-insulin therapies for diabetes market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global non-insulin therapies for diabetes market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global non-insulin therapies for diabetes market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Non-insulin Therapies for Diabetes Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Non-insulin Therapies for Diabetes Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product /Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Non-insulin Therapies for Diabetes Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Class, 2020-2034
    • 6.3.1. Biguanides
    • 6.3.2. Sulfonylureas
    • 6.3.3. Thiazolidinediones
    • 6.3.4. Alpha-Glucosidase Inhibitors
    • 6.3.5. DPP-4 Inhibitors
    • 6.3.6. GLP-1 Analogs
    • 6.3.7. Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
  • 6.4. Market Attractiveness Analysis, by Drug Class

7. Global Non-insulin Therapies for Diabetes Market Analysis and Forecast, by Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Route of Administration, 2020-2034
    • 7.3.1. Oral
    • 7.3.2. Intramuscular
  • 7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Non-insulin Therapies for Diabetes Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2020-2034
    • 8.3.1. Hospital Pharmacy
    • 8.3.2. Retail Pharmacy
    • 8.3.3. Online Pharmacy
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Non-insulin Therapies for Diabetes Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2020-2034
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Non-insulin Therapies for Diabetes Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Drug Class, 2020-2034
    • 10.3.1. Biguanides
    • 10.3.2. Sulfonylureas
    • 10.3.3. Thiazolidinediones
    • 10.3.4. Alpha-Glucosidase Inhibitors
    • 10.3.5. DPP-4 Inhibitors
    • 10.3.6. GLP-1 Analogs
    • 10.3.7. Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
  • 10.4. Market Value Forecast, by Route of Administration, 2020-2034
    • 10.4.1. Oral
    • 10.4.2. Intramuscular
  • 10.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 10.5.1. Hospital Pharmacy
    • 10.5.2. Retail Pharmacy
    • 10.5.3. Online Pharmacy
  • 10.6. Market Value Forecast, by Country, 2020-2034
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Drug Class
    • 10.7.2. By Route of Administration
    • 10.7.3. By Distribution Channel
    • 10.7.4. By Country

11. Europe Non-insulin Therapies for Diabetes Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Drug Class, 2020-2034
    • 11.3.1. Biguanides
    • 11.3.2. Sulfonylureas
    • 11.3.3. Thiazolidinediones
    • 11.3.4. Alpha-Glucosidase Inhibitors
    • 11.3.5. DPP-4 Inhibitors
    • 11.3.6. GLP-1 Analogs
    • 11.3.7. Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
  • 11.4. Market Value Forecast, by Route of Administration, 2020-2034
    • 11.4.1. Oral
    • 11.4.2. Intramuscular
  • 11.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 11.5.1. Hospital Pharmacy
    • 11.5.2. Retail Pharmacy
    • 11.5.3. Online Pharmacy
  • 11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.6.1. Germany
    • 11.6.2. U.K.
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Drug Class
    • 11.7.2. By Route of Administration
    • 11.7.3. By Distribution Channel
    • 11.7.4. By Country/Sub-region

12. Asia Pacific Non-insulin Therapies for Diabetes Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Drug Class, 2020-2034
    • 12.3.1. Biguanides
    • 12.3.2. Sulfonylureas
    • 12.3.3. Thiazolidinediones
    • 12.3.4. Alpha-Glucosidase Inhibitors
    • 12.3.5. DPP-4 Inhibitors
    • 12.3.6. GLP-1 Analogs
    • 12.3.7. Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
  • 12.4. Market Value Forecast, by Route of Administration, 2020-2034
    • 12.4.1. Oral
    • 12.4.2. Intramuscular
  • 12.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 12.5.1. Hospital Pharmacy
    • 12.5.2. Retail Pharmacy
    • 12.5.3. Online Pharmacy
  • 12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.6.1. China
    • 12.6.2. Japan
    • 12.6.3. India
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Drug Class
    • 12.7.2. By Route of Administration
    • 12.7.3. By Distribution Channel
    • 12.7.4. By Country/Sub-region

13. Latin America Non-insulin Therapies for Diabetes Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Drug Class, 2020-2034
    • 13.3.1. Biguanides
    • 13.3.2. Sulfonylureas
    • 13.3.3. Thiazolidinediones
    • 13.3.4. Alpha-Glucosidase Inhibitors
    • 13.3.5. DPP-4 Inhibitors
    • 13.3.6. GLP-1 Analogs
    • 13.3.7. Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
  • 13.4. Market Value Forecast, by Route of Administration, 2020-2034
    • 13.4.1. Oral
    • 13.4.2. Intramuscular
  • 13.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 13.5.1. Hospital Pharmacy
    • 13.5.2. Retail Pharmacy
    • 13.5.3. Online Pharmacy
  • 13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Drug Class
    • 13.7.2. By Route of Administration
    • 13.7.3. By Distribution Channel
    • 13.7.4. By Country/Sub-region

14. Middle East & Africa Non-insulin Therapies for Diabetes Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Drug Class, 2020-2034
    • 14.3.1. Biguanides
    • 14.3.2. Sulfonylureas
    • 14.3.3. Thiazolidinediones
    • 14.3.4. Alpha-Glucosidase Inhibitors
    • 14.3.5. DPP-4 Inhibitors
    • 14.3.6. GLP-1 Analogs
    • 14.3.7. Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
  • 14.4. Market Value Forecast, by Route of Administration, 2020-2034
    • 14.4.1. Oral
    • 14.4.2. Intramuscular
  • 14.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 14.5.1. Hospital Pharmacy
    • 14.5.2. Retail Pharmacy
    • 14.5.3. Online Pharmacy
  • 14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.6.1. GCC Countries
    • 14.6.2. South Africa
    • 14.6.3. Rest of Middle East & Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Drug Class
    • 14.7.2. By Route of Administration
    • 14.7.3. By Distribution Channel
    • 14.7.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2023)
  • 15.3. Company Profiles
    • 15.3.1. GSK plc
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Eli Lilly and Company
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Sumitomo Pharma
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Intarcia Therapeutics
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Servier Laboratories
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Pfizer Inc.
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Merck & Co., Inc.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Dong-A Pharmaceutical Co., Ltd.
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Luye Pharma Group
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Eurofarma Laboratories SA
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Financial Overview
      • 15.3.10.5. Strategic Overview

List of Tables

  • Table 01: Global Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 02: Global Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 03: Global Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 04: Global Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Region, 2020-2034
  • Table 05: North America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Country, 2020-2034
  • Table 06: North America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 07: North America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 08: North America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 09: Europe Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 10: Europe Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 11: Europe Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 12: Europe Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 13: Asia Pacific Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 14: Asia Pacific Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 15: Asia Pacific Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 16: Asia Pacific Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 17: Latin America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 18: Latin America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 19: Latin America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 20: Latin America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 21: Middle East & Africa Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Middle East & Africa Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 23: Middle East & Africa Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 24: Middle East & Africa Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

List of Figures

  • Figure 01: Global Non-insulin Therapies for Diabetes Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034
  • Figure 02: Global Non-insulin Therapies for Diabetes Market Revenue (US$ Bn), by Drug Class, 2023
  • Figure 03: Global Non-insulin Therapies for Diabetes Market Value Share, by Drug Class, 2023
  • Figure 04: Global Non-insulin Therapies for Diabetes Market Revenue (US$ Bn), by Route of Administration, 2023
  • Figure 05: Global Non-insulin Therapies for Diabetes Market Value Share, by Route of Administration, 2023
  • Figure 06: Global Non-insulin Therapies for Diabetes Market Revenue (US$ Bn), by Distribution Channel, 2023
  • Figure 07: Global Non-insulin Therapies for Diabetes Market Value Share, by Distribution Channel, 2023
  • Figure 08: Global Non-insulin Therapies for Diabetes Market Value Share, by Region, 2023
  • Figure 09: Global Non-insulin Therapies for Diabetes Market Value (US$ Bn) Forecast, 2020-2034
  • Figure 10: Global Non-insulin Therapies for Diabetes Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 11: Global Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 12: Global Non-insulin Therapies for Diabetes Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 13: Global Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 14: Non-insulin Therapies for Diabetes Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 15: Global Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 16: Global Non-insulin Therapies for Diabetes Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 17: Global Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 18: North America Non-insulin Therapies for Diabetes Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 19: North America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 20: North America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 21: North America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 22: North America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 23: North America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 24: North America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 25: North America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 26:North America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 27: Europe Non-insulin Therapies for Diabetes Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 28: Europe Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 29: Europe Non-insulin Therapies for Diabetes Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 30: Europe Non-insulin Therapies for Diabetes Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 31: Europe Non-insulin Therapies for Diabetes Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 32: Europe Non-insulin Therapies for Diabetes Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 33: Europe Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 34: Europe Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 35: Europe Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 36: Asia Pacific Non-insulin Therapies for Diabetes Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 37: Asia Pacific Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 38: Asia Pacific Non-insulin Therapies for Diabetes Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 39: Asia Pacific Non-insulin Therapies for Diabetes Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 40: Asia Pacific Non-insulin Therapies for Diabetes Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 41: Asia Pacific Non-insulin Therapies for Diabetes Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 42: Asia Pacific Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 43: Asia Pacific Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 44: Asia Pacific Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 45: Latin America Non-insulin Therapies for Diabetes Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 46: Latin America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 47: Latin America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 48: Latin America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 49: Latin America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 50: Latin America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 51: Latin America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 52: Latin America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 53: Latin America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 54: Middle East & Africa Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 55: Middle East & Africa Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 56: Middle East & Africa Non-insulin Therapies for Diabetes Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 57: Middle East & Africa Non-insulin Therapies for Diabetes Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 58: Middle East & Africa Non-insulin Therapies for Diabetes Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 59: Middle East & Africa Non-insulin Therapies for Diabetes Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 60: Middle East & Africa Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 61: Middle East & Africa Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 62: Middle East & Africa Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Distribution Channel, 2024-2034